Last 12 months
Inside the activity.
5 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 5 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 4 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 6, 2022 01:25 UTC |
Morich FrankDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000899243-22-001051 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 16:05 UTC |
Pienta KennethChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0000899243-21-049172 · doc4.xml · derivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-12-20 F1 · derivative.exercise_date: This stock option grant becomes exercisable in four equal semi-annual installments beginning June 20, 2022. Read SEC document |
| December 15, 2021 Filed Jan 4, 2022 17:00 UTC |
NASSHORN PATRICIAChief Business Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0000899243-22-000537 · doc4.xml · derivative · entry 1 NASSHORN PATRICIA · CIK 0001251374 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-15 F1 · derivative.exercise_date: This stock option grant becomes exercisable in four equal semi-annual installments beginning on June 15, 2022. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 17:00 UTC |
Kiener Peter ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,361 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-21-045070 · doc4.xml · derivative · entry 6 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,744 Underlying: Common Stock · 1,361 shares Expires 2023-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F4 · derivative.exercise_date: The option vests in five equal annual installments beginning March 23, 2017. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 17:00 UTC |
Kiener Peter ADirector
|
SaleCommon Stock | 1,361 | $18.02 | $24,525.22 |
DisclosureSEC source: 0000899243-21-045070 · doc4.xml · nonDerivative · entry 4 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.31, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 17:00 UTC |
Kiener Peter ADirector
|
Exercise / conversionCommon Stock | 1,361 | $2.86 | $3,892.46 |
DisclosureSEC source: 0000899243-21-045070 · doc4.xml · nonDerivative · entry 3 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 17:00 UTC |
Kiener Peter ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 18,815 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-21-045070 · doc4.xml · derivative · entry 5 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,105 Underlying: Common Stock · 18,815 shares Expires 2023-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F4 · derivative.exercise_date: The option vests in five equal annual installments beginning March 23, 2017. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 17:00 UTC |
Kiener Peter ADirector
|
SaleCommon Stock | 18,815 | $17.92 | $337,164.80 |
DisclosureSEC source: 0000899243-21-045070 · doc4.xml · nonDerivative · entry 2 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 17:00 UTC |
Kiener Peter ADirector
|
Exercise / conversionCommon Stock | 18,815 | $2.86 | $53,810.90 |
DisclosureSEC source: 0000899243-21-045070 · doc4.xml · nonDerivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:00 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0000899243-21-045069 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 8,000 shares Expires 2025-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · derivative.exercise_date: The option vests in eight equal semi-annual installments beginning November 14, 2018. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:00 UTC |
Suri AnishPresident and CSO
|
SaleCommon Stock | 8,000 | $18.05 | $144,400.00 |
DisclosureSEC source: 0000899243-21-045069 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,038 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.21, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:00 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 8,000 | $8.26 | $66,080.00 |
DisclosureSEC source: 0000899243-21-045069 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:00 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0000899243-21-044603 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · derivative.exercise_date: The option vests in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:00 UTC |
Suri AnishPresident and CSO
|
SaleCommon Stock | 20,000 | $15.07 | $301,354.00 |
DisclosureSEC source: 0000899243-21-044603 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,038 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.29, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:00 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 20,000 | $6.42 | $128,400.00 |
DisclosureSEC source: 0000899243-21-044603 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:00 UTC |
Suri AnishPRESIDENT AND CSO
|
Tax withholdingCommon Stock | 14,134 | $12.97 | $183,317.98 |
DisclosureSEC source: 0001209191-21-060021 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,038 Read SEC document |
| October 03, 2021 Filed Oct 8, 2021 20:00 UTC |
Suri AnishPRESIDENT AND CSO
|
Exercise / conversionRestricted Stock Units · Derivative | 33,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060021 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019. F3 · derivative.expiration_date: On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019. Read SEC document |
| October 03, 2021 Filed Oct 8, 2021 20:00 UTC |
Suri AnishPRESIDENT AND CSO
|
Exercise / conversionCommon Stock | 33,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060021 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:21 UTC |
Millar Kerri-AnnCHIEF FINANCIAL OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,251 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · derivative · entry 6 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,749 Underlying: Common Stock · 1,251 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021. F6 · derivative.exercise_date: The option vests in eight equal semi-annual installments beginning March 25, 2018. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:21 UTC |
Millar Kerri-AnnCHIEF FINANCIAL OFFICER
|
SaleCommon Stock | 1,251 | $14.21 | $17,782.84 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · nonDerivative · entry 4 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,472 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.46, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:21 UTC |
Millar Kerri-AnnCHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 1,251 | $7.50 | $9,382.50 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · nonDerivative · entry 3 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021. Read SEC document |
| September 30, 2021 Filed Oct 8, 2021 16:00 UTC |
PASSERI DANIEL RDirector · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060022 · doc4.xml · derivative · entry 3 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022. F3 · derivative.expiration_date: One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022. Read SEC document |
| September 30, 2021 Filed Oct 8, 2021 16:00 UTC |
PASSERI DANIEL RDirector · CHIEF EXECUTIVE OFFICER
|
Tax withholdingCommon Stock | 31,677 | $14.57 | $461,533.89 |
DisclosureSEC source: 0001209191-21-060022 · doc4.xml · nonDerivative · entry 2 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,700 Read SEC document |
| September 30, 2021 Filed Oct 8, 2021 16:00 UTC |
PASSERI DANIEL RDirector · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060022 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| September 24, 2021 Filed Sep 27, 2021 16:30 UTC |
PASSERI DANIEL RDirector · CHIEF EXECUTIVE OFFICER
|
PurchaseCommon Stock | 3,400 | $14.72 | $50,051.40 |
DisclosureSEC source: 0001209191-21-057784 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,377 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.749, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC |
Suri AnishPRESIDENT AND CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-21-057785 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F3 · derivative.exercise_date: The option vests in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC |
Suri AnishPRESIDENT AND CSO
|
SaleCommon Stock | 20,000 | $15.23 | $304,646.00 |
DisclosureSEC source: 0001209191-21-057785 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,838 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.58, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC |
Suri AnishPRESIDENT AND CSO
|
Exercise / conversionCommon Stock | 20,000 | $6.42 | $128,400.00 |
DisclosureSEC source: 0001209191-21-057785 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. Read SEC document |
| August 23, 2021 Filed Oct 5, 2021 23:21 UTC |
Millar Kerri-AnnCHIEF FINANCIAL OFFICER
|
Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · derivative · entry 5 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. Read SEC document |
| August 23, 2021 Filed Oct 5, 2021 23:21 UTC |
Millar Kerri-AnnCHIEF FINANCIAL OFFICER
|
Tax withholdingCommon Stock | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · nonDerivative · entry 2 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,472 Read SEC document |
| August 23, 2021 Filed Oct 5, 2021 23:21 UTC |
Millar Kerri-AnnCHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · nonDerivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:00 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 439 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · derivative · entry 6 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,567 Underlying: Common Stock · 439 shares Expires 2024-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:00 UTC |
Pienta KennethChief Medical Officer
|
SaleCommon Stock | 439 | $15.09 | $6,625.65 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · nonDerivative · entry 4 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.22, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:00 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionCommon Stock | 439 | $5.00 | $2,195.00 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · nonDerivative · entry 3 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 16:00 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · derivative · entry 5 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,006 Underlying: Common Stock · 13,000 shares Expires 2024-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 16:00 UTC |
Pienta KennethChief Medical Officer
|
SaleCommon Stock | 13,000 | $15.10 | $196,268.80 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · nonDerivative · entry 2 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.72, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 16:00 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionCommon Stock | 13,000 | $5.00 | $65,000.00 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,994 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · derivative · entry 8 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,006 Underlying: Common Stock · 2,994 shares Expires 2024-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,280 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · derivative · entry 7 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,280 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC |
Pienta KennethChief Medical Officer
|
SaleCommon Stock | 4,274 | $15.06 | $64,345.07 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 5 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionCommon Stock | 2,994 | $5.00 | $14,970.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 4 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionCommon Stock | 1,280 | $2.86 | $3,660.80 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 3 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:44 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · derivative · entry 6 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 Underlying: Common Stock · 16,000 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:44 UTC |
Pienta KennethChief Medical Officer
|
SaleCommon Stock | 16,000 | $15.15 | $242,422.40 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 2 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 to $15.60, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:44 UTC |
Pienta KennethChief Medical Officer
|
Exercise / conversionCommon Stock | 16,000 | $2.86 | $45,760.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:43 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006355 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 17:47 UTC |
PASSERI DANIEL RDirector · CEO
|
GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006358 · doc4.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 17:52 UTC |
Pienta KennethChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006362 · doc4.xml · derivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:49 UTC |
Suri AnishPresident and CSO
|
GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006360 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:43 UTC | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006354 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.